Ethic Inc. Sells 10,454 Shares of Smith & Nephew SNATS, Inc. $SNN

Key Points

• Ethic Inc. reduced its holdings in Smith & Nephew SNATS, Inc. by 30.7% in the first quarter, selling 10,454 shares to own 23,578 shares worth $665,000.
• Several institutional investors have increased their stakes significantly, with Hexagon Capital Partners LLC boosting its holdings by 63.3% and Bessemer Group Inc. growing its investment by 3,471.4%.
• Brokerages have mixed views on Smith & Nephew SNATS, with Canaccord Genuity Group raising its price target to $36.00, while HSBC downgraded its rating from "buy" to "hold."

Ethic Inc. decreased its position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 30.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,578 shares of the medical equipment provider's stock after selling 10,454 shares during the quarter. Ethic Inc.'s holdings in Smith & Nephew SNATS were worth $665,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Bessemer Group Inc. grew its position in Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,701 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Smith & Nephew SNATS during the first quarter worth approximately $211,000. GAMMA Investing LLC grew its position in shares of Smith & Nephew SNATS by 22.4% during the first quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock worth $103,000 after buying an additional 666 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth approximately $435,000. Finally, Barclays PLC acquired a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth approximately $431,000. Institutional investors and hedge funds own 25.64% of the company's stock.

Smith & Nephew SNATS Stock Up 1.5%

Shares of Smith & Nephew SNATS stock traded up $0.5630 during trading on Friday, hitting $37.5330. 603,940 shares of the stock traded hands, compared to its average volume of 984,738. The stock has a market cap of $16.44 billion, a P/E ratio of 17.38, a PEG ratio of 1.03 and a beta of 0.68. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $37.58. The company has a fifty day moving average price of $31.96 and a two-hundred day moving average price of $29.22.

Smith & Nephew SNATS Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be given a $0.285 dividend. This represents a yield of 210.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS's payout ratio is currently 41.20%.

Analyst Ratings Changes

A number of analysts have recently weighed in on SNN shares. Canaccord Genuity Group raised their price target on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research report on Monday, August 18th. HSBC cut Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Hsbc Global Res cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Wall Street Zen cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research note on Friday. Six investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $36.00.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.